Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.39 |
| ▸ | PRCP | P42785 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30359136 | 0.75 | GNAI3 (0.48) | GNAI3GNAO1GNAI1EPHX1PRCP | |
| SCHEMBL25242456 | 0.73 | — | — | |
| SCHEMBL22636087 | 0.71 | — | — | |
| SCHEMBL11708053 | 0.68 | NAMPT (0.51) | EPHX1PRCPNAMPT | |
| SCHEMBL30998613 | 0.66 | CHRM2 (0.39) | EPHX1 | |
| SCHEMBL11126773 | 0.66 | EPHX2 (0.41) | GNAI3GNAO1GNAI1EPHX1PRCP | |
| SCHEMBL22635907 | 0.66 | GNAI3 (0.31) | GNAI3GNAO1GNAI1 | |
| SCHEMBL3241059 | 0.64 | L3MBTL1 (0.39) | GNAI3GNAO1GNAI1EPHX1PRCP | |
| SCHEMBL23123873 | 0.63 | HTT (0.40) | GNAI3GNAO1GNAI1EPHX1PRCP | |
| SCHEMBL5506026 | 0.62 | HTT (0.57) | GNAI3GNAO1GNAI1EPHX1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452264-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452263-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A P2X3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118126-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |